Studies conducted within the NS PARK network – ON GOING inclusions

INDUSTRIAL STUDIES
MOLECULE SPONSOR PHASE STUDY TITLE LINK
Deferiprone ApoPharma II Study of Parkinson's Early Stage With Deferiprone ¤
Agoniste partiel des récepteurs D1/D5 Pfizer II Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations ¤
Agoniste partiel des récepteurs D1/D5 Pfizer II Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease ¤
Solution de lévodopa/carbidopa Neuroderm IIb A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease ¤
ACADEMIC STUDIES
MOLECULE SPONSOR PHASE STUDY TITLE LINK
NA CHU Lille Cohorte Predictive Factors and Subthalamic Stimulation in Parkinson's Disease (PREDI-STIM) ¤
L-threoDops CHU Toulouse IV Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA (DOPS-AMS) ¤
Deferiprone CHU Lille II Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease (FAIRPARKII) ¤
Buspirone AP-HP Créteil III Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease (BUSPARK) ¤
NA CHU Clermont-Ferrand NA One-year Follow-up of Iron in Basal Ganglia - R2*: a Biomarker of Parkinson's Disease Progression? (MPI-R2*) ¤
Apomorphine CHU Rennes III Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP) ¤
Oxycodone / levodopa CHU Toulouse II / III Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease (OXYDOPA) ¤
Botox CHU Clermont-Ferrand III Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor (Btx-HT) ¤
Rivastigmine AP- HM III Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy (RIVA-PSP) ¤
English